These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

117 related articles for article (PubMed ID: 15977973)

  • 1. Gliclazide modified release.
    Rambiritch V; Naidoo P
    Drugs; 2005; 65(10):1449-50. PubMed ID: 15977973
    [No Abstract]   [Full Text] [Related]  

  • 2. Monotherapy of type 2 diabetes with once-daily gliclazide modified release in primary care.
    Ramachandran A
    Diabetes Res Clin Pract; 2003 Oct; 62(1):63-4. PubMed ID: 14581160
    [No Abstract]   [Full Text] [Related]  

  • 3. [Medication of the month. Gliclazide modified release (Uni Diamicron)].
    Scheen AJ
    Rev Med Liege; 2003 Oct; 58(10):641-5. PubMed ID: 14677526
    [TBL] [Abstract][Full Text] [Related]  

  • 4. 24-hour glycemic profile in type 2 diabetic patients treated with gliclazide modified release once daily.
    Guillausseau PJ; Greb W
    Diabetes Metab; 2001 Apr; 27(2 Pt 1):133-7. PubMed ID: 11353879
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Gliclazide modified release: A critical review of pharmacodynamic, metabolic, and vasoprotective effects.
    Schernthaner G
    Metabolism; 2003 Aug; 52(8 Suppl 1):29-34. PubMed ID: 12939737
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Gliclazide modified release.
    McGavin JK; Perry CM; Goa KL
    Drugs; 2002; 62(9):1357-64; discussion 1365-6. PubMed ID: 12076188
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Gliclazide modified release: from once-daily administration to 24-hour blood glucose control.
    Harrower A
    Metabolism; 2000 Oct; 49(10 Suppl 2):7-11. PubMed ID: 11078469
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Controlling of systemic absorption of gliclazide through incorporation into alginate beads.
    Al-Kassas RS; Al-Gohary OM; Al-Faadhel MM
    Int J Pharm; 2007 Aug; 341(1-2):230-7. PubMed ID: 17507189
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The DIACOM study (effect of DosIng frequency of oral Antidiabetic agents on the COMpliance and biochemical control of type 2 diabetes).
    Kardas P
    Diabetes Obes Metab; 2005 Nov; 7(6):722-8. PubMed ID: 16219016
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The "slower" the better.
    Pala L; Rotella CM
    J Endocrinol Invest; 2014 May; 37(5):497-8. PubMed ID: 24658791
    [No Abstract]   [Full Text] [Related]  

  • 11. [The efficacy and safety of 30 mg slow-released-gliclazide in type 2 diabetes mellitus].
    Li GW; Pan CY; Gao Y; Yuan SY; Yang WY; Xing XY; Tian H; Guo XH; Li HB
    Zhonghua Nei Ke Za Zhi; 2004 Jul; 43(7):510-4. PubMed ID: 15312405
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Single and multiple dose bioequivalence evaluation of two brands of gliclazide modified release tablets in healthy Chinese male volunteers.
    Ling G; Sun J; Xu X; Sun Y; He Z
    Arzneimittelforschung; 2006; 56(9):626-30. PubMed ID: 17063637
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [A multicenter clinic study of slow-release-gliclazide in type 2 diabetes mellitus].
    Jia WP; Ning G; Gao X; Yan L; Yang HZ; Li M; Hong J; Lu ZQ; Cheng H; Qi YQ; Li ZW; Xiang KS
    Zhonghua Yi Xue Za Zhi; 2005 Sep; 85(37):2636-9. PubMed ID: 16321325
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Fabrication of Second Generation Smarter PLGA Based Nanocrystal Carriers for Improvement of Drug Delivery and Therapeutic Efficacy of Gliclazide in Type-2 Diabetes Rat Model.
    Panda BP; Krishnamoorthy R; Bhattamisra SK; Shivashekaregowda NKH; Seng LB; Patnaik S
    Sci Rep; 2019 Nov; 9(1):17331. PubMed ID: 31758056
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Swelling behavior of cross-linked dextran hydrogels and preliminary Gliclazide release behavior.
    Bajpai SK; Chand N; Tiwari S; Soni S
    Int J Biol Macromol; 2016 Dec; 93(Pt A):978-987. PubMed ID: 27664925
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Capabilities of hypoglycemic therapy in women with decompensated type 2 diabetes mellitus].
    Onuchin SG; Elsukova OS; Solov'ev OV; Onuchina EL
    Ter Arkh; 2010; 82(8):34-41. PubMed ID: 20873243
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Daily blood glucose profiles of glibenclamide and gliclazide taken once or twice daily in elderly type 2 diabetic patients.
    Kigawa Y; Oba K; Futami-Suda S; Norose J; Yasuoka H; Suzuki K; Ouchi M; Watanabe K; Suzuki T; Nakano H
    Geriatr Gerontol Int; 2008 Sep; 8(3):160-5. PubMed ID: 18821999
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Is gliclazide a sulfonylurea with difference? A review in 2016.
    Singh AK; Singh R
    Expert Rev Clin Pharmacol; 2016 Jun; 9(6):839-51. PubMed ID: 26924475
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Determination of gliclazide minimum concentration in type 2 diabetes mellitus patients.
    Czyrski A; Resztak M; Hermann T
    Biomed Pharmacother; 2018 Oct; 106():1267-1270. PubMed ID: 30119196
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Medium-term hypoglycaemic effects of two different oral formulations of gliclazide.
    Galeone F; Fiore G; Mannucci E
    Diabet Med; 1999 Jul; 16(7):618-9. PubMed ID: 10445842
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 6.